| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 2469.7 | 2363.5 | 2116.2 |
| Other income | 4.0 | 1.9 | 4.5 |
| Total income | 2473.7 | 2365.3 | 2120.7 |
| Profit before exceptional items & tax | 330.9 | 351.9 | 271.0 |
| Exceptional items | -10.3 | 38.1 | 10.4 |
| Profit before tax | 341.2 | 313.8 | 260.6 |
| Net profit | 243.7 | 231.4 | 197.2 |
| Operating margin | 13.8% | 13.3% | 12.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +23.60% |
|---|---|
| Net profit, quarter on quarter | +5.30% |
| Revenue, year on year | +16.70% |
NSE results filing, NSE: EMCURE. Figures extracted from the filing.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,905.90
- Market cap
- ₹36,157 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 35.8×Sector 47.4×
- Promoter holding
- 77.83%-0.04% QoQ
- FII holding
- 4.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure Pharmaceuticals Credit Rating
Emcure Pharmaceuticals received a credit rating reaffirmation from CARE Ratings for its existing bank facilities. The company maintains its stable outlook and financial profile.
Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 as part of its Annual Report.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals has issued a notice for its 45th Annual General Meeting to be held on September 21, 2026. The meeting will address financial statements, dividends, and directorship appointments.